Terbutaline

Pharmacologic Category

Dosing: Adult

Asthma/bronchospasm:

Oral: 5 mg 3 times daily (approximately every 6 hours); reduce dose to 2.5 mg 3 times daily if side effects occur; maximum: 15 mg/24 hours. Note: Oral bronchodilators are not recommended for routine use in the management of acute asthma or long-term daily maintenance treatment due to a slower onset of action and higher risk of side effects compared to inhaled short-acting beta-agonists (GINA 2019; NAEPP 2007).

SubQ: 0.25 mg/dose; may repeat every 20 minutes for 3 doses (maximum: 0.75 mg/1-hour period) (NAEPP 2007)

Manufacturer's labeling: Dosing in the prescribing information may not reflect current clinical practice. 0.25 mg/dose; may repeat in 15 to 30 minutes (maximum: 0.5 mg/4-hour period)

Inhalation: Bricanyl Turbuhaler [Canadian product]: One inhalation (0.5 mg) as needed; if not effective after 5 minutes may repeat dose. If second dose is not effective, consult healthcare provider immediately. Additional doses may be administered however >6 inhalations in a 24 hour period should not be needed. Note: If adequate relief is not obtained with previously effective dose, or if effects of inhalation last <3 hours, patient should be reassessed promptly; may indicate worsening asthma.

Extravasation management, sympathomimetic vasoconstrictors (off-label use; based on limited case reports): SubQ:

Large extravasations: Infiltrate extravasation area using a solution of 1 mg diluted in 10 mL of 0.9% sodium chloride; volume of terbutaline solution administered varied from 3 to 10 mL (Stier 1999).

Small/distal extravasations: Infiltrate extravasation area using a solution of 1 mg diluted in 1 mL of 0.9% sodium chloride; volume of terbutaline solution administered varied from 0.5 to 1 mL (Stier 1999).

Premature labor (acute; short-term [≤72 hours] tocolysis) (off-label use):

IV: 2.5 to 5 mcg/minute; increased gradually every 20 to 30 minutes by 2.5 to 5 mcg/minute up to a maximum of 25 mcg/minute; decrease to the lowest effective dose once contractions are controlled (Mackeen 2014; Travis 1993).

SubQ: 0.25 mg every 20 minutes to 3 hours; hold for pulse >120 beats per minute. Terbutaline has not been approved for and should not be used for prolonged tocolysis (beyond 48 to 72 hours) (ACOG 171 2016; Hearne 2000).

* See Dosage and Administration in AHFS Essentials for additional information.

Dosing: Geriatric

Refer to adult dosing.

Dosing: Renal Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling.

Dosing: Hepatic Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling.

Dosing: Pediatric

Asthma, acute exacerbation:

Continuous infusion: Limited data available, optimal dose not defined, efficacy results variable: Children and Adolescents: Initial: IV bolus dose: 4 to 10 mcg/kg followed by continuous infusion of 0.2 to 0.4 mcg/kg/minute, titrate by 0.1 to 0.2 mcg/kg/minute increments as frequently as every 30 minutes based on patient response or toxicity. Usual maximum dose is 5 mcg/kg/minute; however, doses as high as 10 mcg/kg/minute have been described; monitor closely for adverse reactions (Bogie 2007; Carroll 2006; Doymaz 2018; Kambalapalli 2005; Singhi 2014; Stephanopoulos 1998).

Oral:

Children ≥12 and Adolescents <15 years: 2.5 mg three times daily; maximum daily dose: 7.5 mg/24 hours

Adolescents ≥15 years:5 mg three times daily (approximately every 6 hours); reduce dose to 2.5 mg three times daily if side effects occur; maximum daily dose: 15 mg/24 hours

SubQ:

Children: Limited data available: SubQ: 0.01 mg/kg/dose every 20 minutes for 3 doses; may repeat every 2 to 6 hours as needed (NAEPP 2007)

Adolescents:SubQ: 0.25 mg/dose; may repeat every 20 minutes for up to 3 doses (NAEPP 2007)

Oral inhalation: Canadian labeling: Bricanyl Turbuhaler [Canadian product]: Children ≥6 years and Adolescents: 1 inhalation (0.5 mg) as needed; if not effective after 5 minutes may repeat dose. If second dose is not effective, consult health care provider immediately. Maximum daily dose: 6 inhalations/24 hours.

Dosing: Renal Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling.

Dosing: Hepatic Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling.

Calculations

Use: Labeled Indications

Asthma/Bronchospasm: Prevention and reversal of bronchospasm in patients ≥12 years of age with asthma and reversible bronchospasm associated with bronchitis and emphysema

* See Uses in AHFS Essentials for additional information.

Use: Off-Label: Adult

Extravasation management, sympathomimetic vasoconstrictorsLevel of Evidence [C]

Data from a limited number of patients suggests that terbutaline may be beneficial for the management of extravasation of sympathomimetic vasoconstrictors Ref. Additional data may be necessary to further define the role of terbutaline in this condition.

Premature labor (acute; short-term [≤72 hours] tocolysis)Level of Evidence [G]

The American College of Obstetricians and Gynecologists (ACOG) recommends that terbutaline may be used as a tocolytic agent (short-term [≤72 hours]) in prevention or management of preterm labor Ref.

Level of Evidence Definitions

Level of Evidence Scale

Class and Related Monographs

Sympathomimetics

Clinical Practice Guidelines

Asthma:

Global Strategy for Asthma Management and Prevention (GINA), 2019 Update

NHLBI and NAEPP The Expert Panel Report 3: “Guidelines for the Diagnosis and Management of Asthma,” Full Report 2007

COPD:

ACCP/CTS, “Prevention of Acute Exacerbations of Chronic Obstructive Pulmonary Disease: American College of Chest Physicians and Canadian Thoracic Society Guideline,” 2014

Canadian Thoracic Society Recommendations for Management of Chronic Obstructive Pulmonary Disease, 2007 Update

GOLD, "Global Strategy for Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease," 2019

Exercise-induced Bronchoconstriction:

AAAAI and ACAAI, “Exercise-induced Bronchoconstriction,” Update - 2016

Administration: IV

Use infusion pump.

Administration: Injectable Detail

pH: 4 (solution in vial)

Administration: Oral

Administer around-the-clock to promote less variation in peak and trough serum levels.

Administration: Subcutaneous

Extravasation management, sympathomimetic vasopressors (off-label use): Stop vesicant infusion immediately and disconnect IV line (leave needle/cannula in place); gently aspirate extravasated solution from the IV line (do NOT flush the line); remove needle/cannula; elevate extremity. Infiltrate extravasation area with terbutaline solution 1 mg diluted in 10 mL (large extravasation site) or 1 mg diluted in 1 mL (small/distal extravasation site) of 0.9% sodium chloride into extravasation site (Stier 1999).

Administration: Inhalation

Bricanyl Turbuhaler [Canadian product]: After removing lid, patient should hold inhaler upright and turn blue grip as far as it will go in one direction, then turn it back to original position. Clicking sound indicates that inhaler is ready for use. Patient should exhale fully but not into the inhaler and then place mouthpiece gently between teeth, close lips around inhaler and inhale deeply. Inhaler should be removed from mouth prior to exhaling. Instruct patients to rinse mouth with water after each inhalation as some medication may stick to the inside of the mouth and throat. If inhaler is dropped or shaken, or if patient exhales into the inhaler after a dose is loaded, the dose will be lost and a new dose should be loaded and inhaled. Outside of mouthpiece should be cleaned once weekly with a dry tissue. Instruct patient to keep inhaler dry. First appearance of red mark in dose indicator (window underneath mouthpiece) indicates that 20 doses remain. When red mark reaches bottom of dose indicator no doses remain and Turbuhaler should be discarded.

Administration: Pediatric

Oral: May administer without regard to food; administer around-the-clock to promote less variation in peak and trough serum levels.

Parenteral:

Direct IV injection: Administer undiluted over 5 to 10 minutes

Continuous IV infusion: Administer via an infusion pump at a concentration ≤1 mg/mL (Bogie 2007; Murray 2014; Sinclair-Pingel 2006)

Inhalation: Bricanyl Turbuhaler [Canadian product]: To prepare inhaler prior to use, load dose by holding inhaler in upright position and turn blue grip as far as it will go in one direction and then turn it as far as it will go in the other direction. Prior to first use, this procedure should be done twice; with subsequent dosing, perform this procedure once. Clicking sound means inhaler is loaded with dose and ready for use. Place mouthpiece between teeth and close lips over mouthpiece. Inhale deeply and forcefully. Do not exhale through inhaler. If the Turbuhaler is dropped, shaken, or breathed into after it is loaded, the dose will be lost and a new dose will need to be loaded. When a red mark appears in the dose indicator window, 20 doses are left. When the red mark reaches the bottom of the window, the inhaler should be discarded.

Storage/Stability

Store injection at room temperature; do not freeze. Protect from heat and light. Use only clear solutions. Store powder for inhalation (Bricanyl® Turbuhaler [Canadian availability]) at room temperature between 15°C and 30°C (58°F and 86°F).

Preparation for Administration: Adult

For extravasation management (off-label use): Using vial for injection, dilute 1 mg in 10 mL (large extravasation site) or 1 mg in 1 mL (small/distal extravasation site) of 0.9% sodium chloride (Stier 1999).

Preparation for Administration: Pediatric

Parenteral: Continuous IV infusion: Pediatric patients (asthma): May dilute in D5W or NS to a concentration <1 mg/mL (Murray 2014)

Compatibility

See Trissel’s IV Compatibility Database

Open Trissel's IV Compatibility

Extemporaneously Prepared

A 1 mg/mL oral suspension may be made with tablets. Crush twenty-four 5 mg tablets in a mortar and reduce to a fine powder. Add 5 mL purified water USP and mix to a uniform paste; mix while adding simple syrup, NF in incremental proportions to almost 120 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of simple syrup, NF sufficient to make 120 mL. Label "shake well" and "refrigerate". Stable for 30 days.

Nahata MC, Pai VB, and Hipple TF, Pediatric Drug Formulations, 5th ed, Cincinnati, OH: Harvey Whitney Books Co, 2004.

Medication Patient Education with HCAHPS Considerations

What is this drug used for?

• It is used to open the airways in lung diseases where spasm may cause breathing problems.

• It may be given to you for other reasons. Talk with the doctor.

Frequently reported side effects of this drug

• Fatigue

• Restlessness

• Tremors

Other side effects of this drug: Talk with your doctor right away if you have any of these signs of:

• High blood sugar like confusion, fatigue, increased thirst, increased hunger, passing a lot of urine, flushing, fast breathing, or breath that smells like fruit.

• Low potassium like muscle pain or weakness, muscle cramps, or an abnormal heartbeat.

• Chest pain

• Fast heartbeat

• Abnormal heartbeat

• Severe anxiety

• Severe dizziness

• Passing out

• Severe headache

• Vision changes

• Seizures

• Difficulty breathing

• Wheezing

• Cough

• Signs of a significant reaction like wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat.

Note: This is not a comprehensive list of all side effects. Talk to your doctor if you have questions.

Consumer Information Use and Disclaimer: This information should not be used to decide whether or not to take this medicine or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a brief summary of general information about this medicine. It does NOT include all information about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this medicine. This information is not specific medical advice and does not replace information you receive from the healthcare provider. You must talk with the healthcare provider for complete information about the risks and benefits of using this medicine.

Medication Safety Issues

Sound-alike/look-alike issues:

Contraindications

Hypersensitivity to terbutaline, sympathomimetic amines, or any component of the formulation

Injection: Additional contraindications: Prolonged (>48 to 72 hours) tocolysis, especially for maintenance in the outpatient setting

Oral: Additional contraindications: Acute or maintenance tocolysis

Bricanyl Turbuhaler [Canadian product]: History of tachyarrhythmias; as tocolytic in patients at risk of premature labor or threatened abortion.

Warnings/Precautions

Concerns related to adverse effects:

• Bronchospasm: Rarely, paradoxical bronchospasm may occur with use of inhaled bronchodilating agents; this should be distinguished from inadequate response.

• Hypersensitivity reactions: Immediate hypersensitivity reactions (urticaria, angioedema, rash, bronchospasm) have been reported.

• Serious effects/fatalities: Do not exceed recommended dose; serious adverse events, including fatalities, have been associated with excessive use of inhaled sympathomimetics.

Concurrent drug therapy issues:

• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.

Disease-related concerns:

• Asthma: Appropriate use: When used as a bronchodilator, optimize anti-inflammatory treatment before initiating maintenance treatment with terbutaline. Do not use as a component of chronic therapy without an anti-inflammatory agent. Only the mildest form of asthma (Step 1 and/or exercise-induced) would not require concurrent use based upon asthma guidelines.

• Cardiovascular disease: Use with caution in patients with cardiovascular disease (arrhythmia or hypertension or HF); beta-agonists may cause elevation in blood pressure, heart rate and result in CNS stimulation/excitation. Beta2-agonists may also increase risk of arrhythmias.

• Diabetes: Use with caution in patients with diabetes mellitus; beta2-agonists may increase serum glucose.

• Glaucoma: Use with caution in patients with glaucoma; may elevate intraocular pressure.

• Hyperthyroidism: Use with caution in hyperthyroidism; may stimulate thyroid activity.

• Hypokalemia: Use with caution in patients with hypokalemia or taking concomitant drugs that cause hypokalemia; beta2-agonists may decrease serum potassium.

• Preterm labor: [US Boxed Warning]: Terbutaline is not FDA approved for and should not be used for prolonged tocolysis (>48 to 72 hours). Use for maintenance tocolysis should not be done in the outpatient setting. Adverse events observed in pregnant women include arrhythmias, increased heart rate, hyperglycemia (transient), hypokalemia, myocardial ischemia, and pulmonary edema. Heart rate may be increased in the fetus and hypoglycemia may occur in the neonate. Oral terbutaline is contraindicated for acute or chronic use in the management of preterm labor.

• Seizures: Use with caution in patients with seizure disorders; beta-agonists may result in CNS stimulation/excitation.

Other warnings/precautions:

• Patient information: Patients must be instructed to seek medical attention in cases where acute symptoms are not relieved or a previous level of response is diminished. The need to increase frequency of use may indicate deterioration of asthma, and treatment must not be delayed.

* See Cautions in AHFS Essentials for additional information.

Geriatric Considerations

Oral terbutaline should be avoided in the elderly due to the increased incidence of adverse effects as compared to the inhaled form.

Pregnancy Considerations

Terbutaline crosses the placenta; umbilical cord concentrations are ~11% to 48% of maternal blood levels.

Terbutaline may affect uterine contractility; use caution if needed to control bronchospasm in pregnant women. Uncontrolled asthma is associated with adverse events in pregnancy (increased risk of perinatal mortality, preeclampsia, preterm birth, low birth weight infants). Poorly controlled asthma or asthma exacerbations may have a greater fetal/maternal risk than what is associated with appropriately used asthma medications. Terbutaline is not one of the preferred agents for the initial treatment of asthma during pregnancy (ACOG 90 2008; GINA 2019; NAEPP 2007).

[US Boxed Warning]: Terbutaline injection has not been approved for and should not be used for prolonged tocolysis (beyond 48 to 72 hours). Oral terbutaline sulfate has not been approved and should not be used for acute or maintenance tocolysis. In particular, terbutaline should not be used for maintenance tocolysis in the outpatient or home setting. Serious adverse reactions, including death, have been reported after administration of terbutaline to pregnant women. In mothers, these adverse reactions include increased heart rate, transient hyperglycemia, hypokalemia, cardiac arrhythmias, pulmonary edema, and myocardial ischemia. Increased fetal heart rate and neonatal hypoglycemia may occur as a result of maternal administration. Terbutaline has been used in the management of preterm labor. Tocolytics may be used for the short-term (48 hour) prolongation of pregnancy to allow for the administration of antenatal steroids and should not be used prior to fetal viability or when the risks of use to the fetus or mother are greater than the risk of preterm birth (ACOG 171 2016).

Breast-Feeding Considerations

Terbutaline is present in breast milk; concentrations are similar to or higher than those in the maternal plasma. Based on information from four cases, exposure to the breastfed infant would be <1% of the weight-adjusted maternal dose. Adverse events were not observed in nursing infants (Boréus 1982; Lönnerholm 1982). The manufacturer recommends that terbutaline be used in breastfeeding women only if the potential benefit to the mother outweighs the possible risk to the infant.

Briggs' Drugs in Pregnancy & Lactation

Terbutaline

Adverse Reactions

>10%:

Central nervous system: Nervousness, restlessness

Endocrine & metabolic: Decreased serum potassium, increased serum glucose

Neuromuscular & skeletal: Tremor

1% to 10%:

Cardiovascular: Hypertension, tachycardia

Central nervous system: Dizziness, drowsiness, headache, insomnia

Dermatologic: Diaphoresis

Gastrointestinal: Dysgeusia, nausea, vomiting, xerostomia

Neuromuscular & skeletal: Muscle cramps, weakness

<1%, postmarketing, and/or case reports: Cardiac arrhythmia, chest pain, hyperglycemia (preterm labor), hypokalemia (preterm labor), hypotension (preterm labor), ischemic heart disease (preterm labor), lactic acidosis (Smith 2019), myocardial infarction (preterm labor), paradoxical bronchospasm, pulmonary edema (preterm labor)

* See Cautions in AHFS Essentials for additional information.

Toxicology

Beta Agonists

Metabolism/Transport Effects

None known.

Drug Interactions Open Interactions

AtoMOXetine: May enhance the tachycardic effect of Beta2-Agonists. Risk C: Monitor therapy

AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics. Risk C: Monitor therapy

Atosiban: Beta2-Agonists may enhance the adverse/toxic effect of Atosiban. Specifically, there may be an increased risk for pulmonary edema and/or dyspnea. Risk C: Monitor therapy

Beta-Blockers (Beta1 Selective): May diminish the bronchodilatory effect of Beta2-Agonists. Of particular concern with nonselective beta-blockers or higher doses of the beta1 selective beta-blockers. Risk C: Monitor therapy

Beta-Blockers (Nonselective): May diminish the bronchodilatory effect of Beta2-Agonists. Risk X: Avoid combination

Betahistine: May diminish the therapeutic effect of Beta2-Agonists. Risk C: Monitor therapy

Cannabinoid-Containing Products: May enhance the tachycardic effect of Sympathomimetics. Exceptions: Cannabidiol. Risk C: Monitor therapy

Cocaine (Topical): May enhance the hypertensive effect of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use. Risk D: Consider therapy modification

Doxofylline: Sympathomimetics may enhance the adverse/toxic effect of Doxofylline. Risk C: Monitor therapy

Guanethidine: May enhance the arrhythmogenic effect of Sympathomimetics. Guanethidine may enhance the hypertensive effect of Sympathomimetics. Risk C: Monitor therapy

Haloperidol: QT-prolonging Agents (Indeterminate Risk - Caution) may enhance the QTc-prolonging effect of Haloperidol. Risk C: Monitor therapy

Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid. Specific dose adjustment recommendations are not presently available. Risk D: Consider therapy modification

Loop Diuretics: Beta2-Agonists may enhance the hypokalemic effect of Loop Diuretics. Risk C: Monitor therapy

Loxapine: Agents to Treat Airway Disease may enhance the adverse/toxic effect of Loxapine. More specifically, the use of Agents to Treat Airway Disease is likely a marker of patients who are likely at a greater risk for experiencing significant bronchospasm from use of inhaled loxapine. Management: This is specific to the Adasuve brand of loxapine, which is an inhaled formulation. This does not apply to non-inhaled formulations of loxapine. Risk X: Avoid combination

Methacholine: Beta2-Agonists (Short-Acting) may diminish the therapeutic effect of Methacholine. Management: Hold short-acting beta2 agonists for 6 hours before methacholine use. Risk D: Consider therapy modification

Monoamine Oxidase Inhibitors: May enhance the adverse/toxic effect of Beta2-Agonists. Risk C: Monitor therapy

Ozanimod: May enhance the hypertensive effect of Sympathomimetics. Management: Concomitant use of ozanimod with sympathomimetic agents is not recommended. If combined, monitor patients closely for the development of hypertension, including hypertensive crises. Risk D: Consider therapy modification

QT-prolonging Agents (Highest Risk): QT-prolonging Agents (Indeterminate Risk - Caution) may enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk C: Monitor therapy

Solriamfetol: Sympathomimetics may enhance the hypertensive effect of Solriamfetol. Sympathomimetics may enhance the tachycardic effect of Solriamfetol. Risk C: Monitor therapy

Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics. Risk C: Monitor therapy

Tedizolid: May enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics. Risk C: Monitor therapy

Thiazide and Thiazide-Like Diuretics: Beta2-Agonists may enhance the hypokalemic effect of Thiazide and Thiazide-Like Diuretics. Risk C: Monitor therapy

Tricyclic Antidepressants: May enhance the adverse/toxic effect of Beta2-Agonists. Risk C: Monitor therapy

Genes of Interest

Monitoring Parameters

Serum potassium, glucose; intake/output; heart rate, blood pressure, respiratory rate; chest pain, shortness of breath; monitor for signs and symptoms of pulmonary edema (when used as a tocolytic); monitor FEV1, peak flow, and/or other pulmonary function tests (when used as bronchodilator). If used for extravasation management, monitor and document extravasation site.

Advanced Practitioners Physical Assessment/Monitoring

Respiratory use: For inpatient care, monitor vital signs and lung sounds prior to and periodically during therapy. Preterm labor use: Inpatient: Monitor maternal vital signs; respiratory, fluid, cardiac, and electrolyte status; frequency, duration, and intensity of contractions; and fetal heart rate. Common side effects: Nervousness, drowsiness, headache, palpitations, tachycardia, nausea, and tremors. Use with caution in patients with cardiovascular disorders including coronary insufficiency, hypertension, and cardiac arrhythmias.

Nursing Physical Assessment/Monitoring

Respiratory use: Monitor for cardiac and CNS changes at beginning of therapy and periodically throughout. For inpatient care, monitor vital signs and lung sounds prior to and periodically during therapy. Preterm labor use: Inpatient: Monitor maternal vital signs; respiratory, fluid, cardiac, and electrolyte status; frequency, duration, and intensity of contractions; and fetal heart rate. Subcutaneous administration only; not intravenous administration. Monitor for common side effects: Nervousness, drowsiness, headache, palpitations, tachycardia, nausea, and tremors.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution, Injection, as sulfate:

Generic: 1 mg/mL (1 mL)

Solution, Injection, as sulfate [preservative free]:

Generic: 1 mg/mL (1 mL)

Tablet, Oral, as sulfate:

Generic: 2.5 mg, 5 mg

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Aerosol Powder Breath Activated, Inhalation:

Bricanyl Turbuhaler: 0.5 mg/actuation (1 ea)

Anatomic Therapeutic Chemical (ATC) Classification

R03AC03
R03CC03

Generic Available (US)

Yes

Pricing: US

Solution (Terbutaline Sulfate Injection)

1 mg/mL (per mL): $2.16 - $21.59

Tablets (Terbutaline Sulfate Oral)

2.5 mg (per each): $5.44 - $13.73

5 mg (per each): $6.65 - $16.77

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Mechanism of Action

Relaxes bronchial and uterine smooth muscle by action on beta2-receptors with less effect on heart rate

Pharmacodynamics/Kinetics

Onset of action: Oral: 30 to 45 minutes; SubQ: 6 to 15 minute; Inhalation: 5 minutes (maximum effect: 15 to 60 minutes)

Duration: Oral: 4 to 8 hours; Oral inhalation: 3 to 6 hours; SubQ: 1.5 to 4 hours

Absorption: 33% to 50%

Protein binding: 25%

Metabolism: Hepatic to inactive sulfate conjugates

Bioavailability: SubQ doses are more bioavailable than oral

Half-life elimination: 5.7 hours (range: 2.9 to 14 hours)

Time to peak, serum: SubQ: 0.5 hours

Excretion: Urine (60% as unchanged drug); feces

Local Anesthetic/Vasoconstrictor Precautions

No information available to require special precautions

Effects on Dental Treatment

Key adverse event(s) related to dental treatment: Xerostomia (normal salivary flow resumes upon discontinuation) and bad taste in mouth.

Effects on Bleeding

No information available to require special precautions

Related Information

Management of Drug Extravasations

Index Terms

Brethaire; Brethine; Bricanyl; Terbutaline Sulfate

FDA Approval Date

May 17, 1976

References

American College of Obstetricians and Gynecologists (ACOG). ACOG practice bulletin: clinical management guidelines for obstetrician-gynecologists number 90, February 2008: asthma in pregnancy. Obstet Gynecol. 2008;111(2 Pt 1):457-464.[PubMed 18238988]

American College of Obstetricians and Gynecologists (ACOG). Practice Bulletin No. 171: Management of Preterm Labor. Obstet Gynecol. 2016;128(4):e155-e164. doi: 10.1097/AOG.0000000000001711.[PubMed 27661654]

Berkman ND, Thorp JM Jr, Hartmann KE, et al, "Management of Preterm Labor," Evidence Report/Technology Assessment No. 18 (Prepared by Research Triangle Institute under Contract No. 290-97-0011). AHRQ Publication No. 01-E021. Rockville (MD) Agency for Healthcare Research and Quality. December 2000.[PubMed 11127122]

Bogie AL, Towne D, Luckett PM, Abramo TJ, Wiebe RA. Comparison of intravenous terbutaline versus normal saline in pediatric patients on continuous high-dose nebulized albuterol for status asthmaticus. Pediatr Emerg Care. 2007;23(6):355-361.[PubMed 17572517 ]

Bohn D, Kalloghlian A, Jenkins J, et al, “Intravenous Salbutamol in the Treatment of Status Asthmaticus in Children,” Crit Care Med, 1984, 12(10):892-6.[PubMed 6435957]

Boréus LO and de Château PU, "Terbutaline in Breast Milk," Br J Clin Pharmacol, 1982, 13(5):731-2.[PubMed 7082542]

Bricanyl Turbuhaler (terbutaline) [product monograph]. Mississauga, Ontario, Canada: AstraZeneca Canada Inc; January 2018.

Canny GJ and Levison H, “Aerosols - Therapeutic Use and Delivery in Childhood Asthma,” Ann Allergy, 1988, 60(1):11-9.[PubMed 3276242]

Carroll CL, Schramm CM. Protocol-based titration of intravenous terbutaline decreases length of stay in pediatric status asthmaticus. Pediatr Pulmonol. 2006;41(4):350-356.[PubMed 16502398]

Doymaz S, Schneider J. Safety of terbutaline for treatment of acute severe pediatric asthma. Pediatr Emerg Care. 2018;34(5):299-302.[PubMed 26959519]

Fuglsang G, Pedersen S, and Borgstrom L, “Dose-Response Relationships of I.V. Administered Terbutaline in Children With Asthma,” J Pediatr, 1989, 114(2):315-20.[PubMed 2915294]

Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. https://ginasthma.org/wp-content/uploads/2019/06/GINA-2019-main-report-June-2019-wms.pdf. Updated 2019. Accessed September 23, 2019.

Goldenhersh N and Rachelefsky GS, “Childhood Asthma: Management,” Pediatr Rev, 1989, 10(9):259-67.[PubMed 2652119]

Guinn DA, Goepfert AR, Owen J, et al, “Terbutaline Pump Maintenance Therapy for Prevention of Preterm Delivery: A Double-Blind Trial,” Am J Obstet Gynecol, 1998, 179(4):874-8.[PubMed 9790362]

Hearne AE and Nagey DA, "Therapeutic Agents in Preterm Labor: Tocolytic Agents," Clin Obstet Gynecol 2000, 43(4):787-801.[PubMed 11100296]

Kambalapalli M, Nichani S, Upadhyayula S. Safety of intravenous terbutaline in acute severe asthma: a retrospective study. Acta Paediatr. 2005;94(9):1214-1217.[PubMed 16203672]

Kelly HW, McWilliams BC, Katz R, et al, “Safety of Frequent High Dose Nebulized Terbutaline in Children With Acute Severe Asthma,” Ann Allergy, 1990, 64(2 Pt 2):229-33.[PubMed 2301784]

Lam F, Gill P, Smith M, et al, “Use of the Subcutaneous Terbutaline Pump for Long-Term Tocolysis,” Obstet Gynecol, 1998, 72(5):810-3.

Lönnerholm G and Lindström B, "Terbutaline Excretion Into Breast Milk," Br J Clin Pharmacol, 1982, 13(5):729-30.[PubMed 7082541]

Mackeen AD, Seibel-Seamon J, Muhammad J, Baxter JK, Berghella V. Tocolytics for preterm premature rupture of membranes. Cochrane Database Syst Rev. 2014;(2):CD007062.[PubMed 24578236]

Murray KL, Wright D, Laxton B, Miller KM, Meyers J, Englebright J. Implementation of standardized pediatric i.v. medication concentrations. Am J Health Syst Pharm. 2014;71(17):1500-1508.[PubMed 25147175 ]

National Asthma Education and Prevention Program (NAEPP), Expert Panel Report 3, "Guidelines for the Diagnosis and Management of Asthma," Clinical Practice Guidelines, National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 08-4051, prepublication 2007. Available at http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm

Rachelefsky GS and Siegel SC, “Asthma in Infants and Children - Treatment of Childhood Asthma: Part II,” J Allergy Clin Immunol, 1985, 76(3):409-25.[PubMed 2863296]

Simhav HN and Caritis SN, “Prevention of Preterm Delivery,” N Engl J Med, 2007, 357(5):477-87.[PubMed 17671256]

Sinclair-Pingel J, Grisso AG, Hargrove FR, Wright L. Implementation of standardized concentrations for continuous infusions using a computerized provider Oder Entry System [published correction appears in Hosp Pharm. 2007;42:84-85]. Hosp Pharm. 2006;41(11):1102-1106.

Singhi S, Grover S, Bansal A, Chopra K. Randomised comparison of intravenous magnesium sulphate, terbutaline and aminophylline for children with acute severe asthma. Acta Paediatr. 2014;103(12):1301-1306.[PubMed 25164315]

Smith ZR, Horng M, Rech MA. Medication-induced hyperlactatemia and lactic acidosis: a systematic review of the literature. Pharmacotherapy. 2019;39(9):946-963.[PubMed 31361914]

Stephanopoulos DE, Monge R, Schell KH, Wyckoff P, Peterson BM. Continuous intravenous terbutaline for pediatric status asthmaticus. Crit Care Med. 1998;26(10):1744-1748.[PubMed 9781734]

Stier PA, Bogner MP, Webster K, et al, "Use of Subcutaneous Terbutaline to Reverse Peripheral Ischemia," Am J Emerg Med, 1999, 17(1):91-4.[PubMed 9928712]

Terbutaline sulfate injection [package insert]. Bedford, OH: Bedford Laboratories; April 2011.

Terbutaline sulfate tablet [prescribing information]. Baudette, MN: ANI Pharmaceuticals; September 2018.

Tipton WR and Nelson HS, “Frequent Parenteral Terbutaline in the Treatment of Status Asthmaticus in Children,” Ann Allergy, 1987, 58(4):252-6.[PubMed 3565860]

Travis BE and McCullough JM, “Pharmacotherapy of Preterm Labor,” Pharmacotherapy, 1993, 13(1):28-36.[PubMed 8437965]

Zehner WJ Jr, Scott JM, Iannolo PM, et al, “Terbutaline vs Albuterol for Out-of-Hospital Respiratory Distress: Randomized Double-Blind Trial,” Acad Emerg Med, 1995, 2(8):686-91.[PubMed 7584746]

Brand Names: International

Aironyl (EG, QA); Asmaline (TH); Asthmasian (TH); Ataline (LK, MY); Beta-2 (KR); Betamic (BD); Brethin (LK); Bricalin (IL); Bricanil (VE); Bricanyl (AE, AR, AT, AU, BB, BF, BJ, BM, BR, BS, BZ, CH, CI, CN, CY, CZ, DK, EG, ET, FI, FR, GB, GH, GM, GN, GY, HK, HU, IE, IL, IN, IQ, IR, IS, IT, JM, JO, KE, KR, LB, LR, LU, LY, MA, ML, MR, MT, MU, MW, MY, NE, NG, NL, NO, NZ, OM, PE, PH, PK, PT, QA, RO, SA, SC, SD, SE, SG, SL, SN, SR, SY, TN, TR, TT, TW, TZ, UG, VN, YE, ZA, ZM, ZW); Bricanyl Depot (NO); Bricanyl EX (CR, DO, GT, HN, NI, PA, SV); Bricanyl Turbuhaler (HU, PL); Bricasma (ID); Bricasol (BD); Britaline (MY); Bronchodam (PH); Bronclyn (BH); Bronco Asmo (TH); Bronconyl (TH); Brothine (TW); Bucanil (MY, SG); Bucaril (TH); Butaline (MY); Contimit (DE); Dilanyl (BH); Draconyl (GR); Getran (TW); Glin (TW); Nairet (VN); Nairex (ID); Neoterb (AE, KW, QA); Pulmoxel (PH); Samisil (BD); Talin (QA); Tebif (LK); Terbasmin (ES, IT); Terbron (MY); Terbu Expectorant (TH); Terbul (LU); Terbulin (BD, IL); Terburop (CO, EC); Terbutalin AL (HU); Terbutalin Stada (PL); Terbutanyl (EG); Terbutil (BR); Tervent (BD)

Last Updated 4/8/20

Google Sites

Report abuse